Cardiac Triple Master Plate

Your current location：HomePRODUCTSFluorescence immunochromatographic plate

Cardiac triple markers—cTnI (cardiac troponin I), MYO (myoglobin) and CK-MB (creatine kinase-MB)—are clinically recognized core biomarkers for early screening, dynamic monitoring and prognostic evaluation of acute myocardial infarction (AMI). The three markers complement each other: MYO rises earliest for ultra-early AMI screening; cTnI boasts superior specificity as the gold standard for myocardial injury diagnosis; classic CK-MB assists condition confirmation and disease course judgment. Combined testing drastically improves diagnostic accuracy for acute cardiovascular events, serving as an essential routine assay in clinical laboratories, emergency and cardiology departments across all tiers of hospitals.

Product Introduction
Product Features
FAQ/Experimental Cases
Manual Download

Existing Pain Points of Traditional Cardiac Triple Testing

Traditional single-item kits and small combined test strips bring multiple drawbacks in high-throughput routine testing, impairing diagnosis efficiency and result accuracy:

∠ Poor early detection performance: Low sensitivity at low concentrations leads to missed diagnosis of ultra-early myocardial injury and delayed treatment;

∠ Narrow linear range: Hook effect occurs in high-concentration samples, yielding falsely low readings that fail to reflect true biomarker levels of severe patients;

∠ Unstable repeatability: Large intra- and inter-batch CV fluctuations for combined triple testing, causing obvious deviation in repeated tests of identical specimens;

∠ Limited throughput efficiency: Conventional kit formats cannot meet high-volume testing demands.

DIA-UP Cardiac Triple Master Plate

Stable batch performance · traceable results · compatible QC · mass-production ready

To address above clinical challenges, DIA-UP’s cTnI · MYO · CK-MB cardiac triple master plate features full-process technical upgrades, balancing analytical performance, metrological traceability, quality control consistency and high throughput for clinical large-sample testing:

Ultra-high sensitivity for rapid early screening

Optimized antigen-antibody pairs and reaction systems greatly boost low-concentration detection capacity to capture trace myocardial biomarkers, cutting missed diagnosis risks of early myocardial injury and supporting fast clinical screening.

Broad linear range covering all patient conditions

Extended linear intervals eliminate bias for high-value specimens, delivering stable reliable readings across mild to severe patient biomarker levels.

Consistent batch-to-batch performance for reliable results

Specialized calibration for the triple assay minimizes intra- and inter-batch variation of cTnI, MYO and CK-MB. Validated over 10 production batches annually, it maintains stable quality for challenging specimens with consistent results in repeated and bulk testing.

Fully traceable & compatible with mainstream QC materials

With annual output of 10 million test dosages, all results are traceable to chemiluminescence platforms. Precisely calibrated plates work seamlessly with mainstream third-party QC products including Bio-Rad and Randox, simplifying daily quality control workflows.

Master plate format for large-scale manufacturing

Master plate design enables mass production, lifting manufacturing throughput and finished-kit preparation efficiency while lowering overall production costs.

DIA-UP BIOTECH

Performance Verification

● cTnI Clinical Correlation Test

Excellent clinical correlation against well-known imported brands with R²=0.956

心肌三项联检大板